Aura Biosciences (NASDAQ:AURA) granted inducement equity awards to new CEO and President Natalie Holles on May 19, 2026 under Nasdaq Rule 5635(c)(4).
The package includes options for 2,169,103 shares at $7.39, 600,118 RSUs, and 553,844 PRSUs, all subject to multi‑year time and, for PRSUs, performance vesting conditions.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
Inducement equity aligns new CEO compensation with long-term share performance
Option grant for 2,169,103 shares at $7.39 exercise price
RSUs for 600,118 shares and PRSUs for 553,844 shares awarded
Four-year vesting structure supports multi-year leadership retention and incentives
Negative
Potential dilution from 3,323,065 shares underlying options, RSUs, and PRSUs
Unmet PRSU performance conditions could result in forfeiture of awards
News Market Reaction – AURA
+2.71%
1 alert
+2.71%News Effect
+$21MValuation Impact
$795.56MMarket Cap
0.0xRel. Volume
On the day this news was published, AURA gained 2.71%, reflecting a moderate positive market reaction.
This price movement added approximately $21M to the company's valuation, bringing the market cap to $795.56M at that time.
Stock options granted:2,169,103 sharesOption exercise price:$7.39 per shareTime-based RSUs:600,118 shares+5 more
8 metrics
Stock options granted2,169,103 sharesNon-qualified stock options in CEO inducement award
Option exercise price$7.39 per shareEqual to closing price on May 19, 2026 (Grant Date)
Time-based RSUs600,118 sharesRestricted stock units granted to new CEO
Performance RSUs553,844 sharesPerformance-based RSUs subject to time and performance conditions
Initial option vesting25%Vests and becomes exercisable on April 30, 2027
Ongoing option vesting2.0834% monthlyMonthly vesting over 36 months after April 30, 2027
RSU vesting start25% on April 15, 2027First Vesting Date for CEO RSUs
PRSUs expiration6th anniversary of Grant DatePRSUs expire if unvested by earlier of 6 years or end of service
Market Reality Check
Price:$6.21Vol:Volume 554,439 is at 0.71...
normal vol
$6.21Last Close
VolumeVolume 554,439 is at 0.71x the 20-day average of 783,613, indicating subdued trading activity.normal
TechnicalShares at $7.39 are trading above the 200-day MA of $6.22 and 22.5% below the 52-week high of $9.535.
Peers on Argus
AURA was down 3.49% while momentum peers like BCYC and AUTL in the scanner were ...
2 Up
AURA was down 3.49% while momentum peers like BCYC and AUTL in the scanner were moving up, and core biotech peers showed a mix of modest gains and notable declines, pointing to a stock-specific move tied more to company events than a uniform sector trend.
Launch of proposed public equity and pre-funded warrant offering from shelf.
Pattern Detected
Recent financing and earnings events tended to see share price moves that mostly aligned with the positive or negative tone of the news, with one offering-related announcement showing a positive divergence.
Recent Company History
Over the last weeks, Aura reported Q1 2026 results and highlighted progress of its Phase 3 CoMpass trial, alongside a wider net loss of $33.7 million. The company executed a large underwritten public offering and related pre-funded warrants, raising gross proceeds near $299.4 million and outlining plans to repurchase up to 6,922,870 shares from Matrix. Conference participation and investor outreach followed. Today’s inducement grants to new CEO Natalie Holles build on those governance and financing developments, formalizing her equity-based compensation.
Market Pulse Summary
This announcement details a standard inducement equity package for Aura’s new CEO, including stock o...
Analysis
This announcement details a standard inducement equity package for Aura’s new CEO, including stock options, RSUs and PRSUs at an exercise price of $7.39. It follows recent financings, share repurchases and a quarter marked by a net loss of $33.7 million as late-stage development continued. Investors may watch how these incentives align management with longer-term value creation, alongside progress in the Phase 3 CoMpass trial and the company’s evolving post-offering shareholder base.
"were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-qualified stock optionsfinancial
"consist of (i) non-qualified stock options to purchase an aggregate of 2,169,103 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
restricted stock unitsfinancial
"(ii) restricted stock units (“RSUs”) for 600,118 shares of Common Stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance-based rsusfinancial
"(iii) performance-based RSUs (“PRSUs”) for 553,844 shares of Common Stock."
Performance-based restricted stock units (RSUs) are promises to deliver company shares to employees only if the business meets specific goals, such as revenue, profit, stock-price targets, or strategic milestones. For investors, they matter because they change future share supply and align management incentives with company results—like a salesperson whose bonus only pays out when sales targets are hit—so they can affect earnings, dilution, and confidence in leadership.
exercise pricefinancial
"with an exercise price of $7.39 per share, which is equal to the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"The Option Award will vest as follows: 25% shall vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura’s new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles’ offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Awards consist of (i) non-qualified stock options to purchase an aggregate of 2,169,103 shares of the Company’s common stock (“Common Stock”) with an exercise price of $7.39 per share, which is equal to the closing price of the Common Stock as reported by Nasdaq on the Grant Date (the “Option Award”), (ii) restricted stock units (“RSUs”) for 600,118 shares of Common Stock, and (iii) performance-based RSUs (“PRSUs”) for 553,844 shares of Common Stock. The Option Award will vest as follows: 25% shall vest and become exercisable on April 30, 2027, and 2.0834% shall vest and become exercisable on a monthly basis thereafter over the following 36 months, subject to Ms. Holles’ continued service as of each vesting date. The RSUs will vest as follows: 25% shall vest on April 15, 2027 (the “First Vesting Date”), and 25% shall vest on each of the first year anniversary, second year anniversary, and third year anniversary of the First Vesting Date, subject to Ms. Holles’ continued service as of each vesting date. The PRSUs will be subject to both time-based vesting and the achievement of a performance condition, both of which must be satisfied before the PRSUs will be deemed vested. The PRSUs shall vest in four substantially equal annual installments commencing on the First Vesting Date, subject to Ms. Holles’ continued service as of each such time-based vesting date and the satisfaction of the performance condition. The expiration date of the PRSUs shall be the earlier of (i) the sixth (6th) anniversary of the Grant Date and (ii) the date Ms. Holles no longer has a service relationship with the Company. Any such PRSUs that have not vested on or prior to such expiration date shall be forfeited for no consideration.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Aura’s lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura is headquartered in Boston, MA. Aura’s mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
For more information, visit aurabiosciences.com. Follow us on X, @AuraBiosciences, and visit us on LinkedIn.
Investor and Media Relations Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
What inducement equity awards did Aura Biosciences (NASDAQ:AURA) grant to its new CEO?
Aura Biosciences granted stock options, RSUs, and PRSUs to new CEO Natalie Holles. According to Aura Biosciences, the package includes options for 2,169,103 shares, 600,118 RSUs, and 553,844 PRSUs, all structured as employment inducement awards.
When were the Aura Biosciences (AURA) inducement grants to Natalie Holles made?
The inducement grants to Natalie Holles were made on May 19, 2026. According to Aura Biosciences, this Grant Date sets the $7.39 option exercise price and anchors the multi-year vesting schedules for options, RSUs, and performance-based RSUs.
How do the Aura Biosciences (AURA) CEO stock options and RSUs vest?
The CEO options and RSUs vest over four years, subject to continued service. According to Aura Biosciences, options vest 25% by April 30, 2027 then monthly; RSUs vest 25% on April 15, 2027 and annually thereafter in equal installments.
How are Aura Biosciences (AURA) performance-based RSUs for the CEO structured?
The CEO’s PRSUs require both time-based vesting and a performance condition. According to Aura Biosciences, PRSUs vest in four equal annual installments starting April 15, 2027, only if the performance condition is satisfied; unvested PRSUs expire by the sixth anniversary.
What does Nasdaq Listing Rule 5635(c)(4) mean for Aura Biosciences (AURA) inducement grants?
Nasdaq Rule 5635(c)(4) allows equity awards as a material employment inducement without shareholder approval. According to Aura Biosciences, the Board approved these CEO inducement awards in line with this rule and the previously disclosed offer letter terms.
Could the Aura Biosciences (AURA) CEO inducement awards dilute existing shareholders?
The CEO inducement awards could be dilutive if fully vested and settled in shares. According to Aura Biosciences, the package covers 2,169,103 option shares plus 600,118 RSUs and 553,844 PRSUs, all additive to existing common stock over time.
